Venbio Select Advisor Increased By $224.90 Million Its Immunomedics (IMMU) Position; MARAPHARM VENTURES ORDINARY SHARES (MRPHF) Sellers Decreased By 31.74% Their Shorts

June 8, 2018 - By wolcottdaily

Immunomedics, Inc. (NASDAQ:IMMU) Logo

MARAPHARM VENTURES INC ORDINARY SHARES (OTCMKTS:MRPHF) had a decrease of 31.74% in short interest. MRPHF’s SI was 88,400 shares in June as released by FINRA. Its down 31.74% from 129,500 shares previously. With 136,100 avg volume, 1 days are for MARAPHARM VENTURES INC ORDINARY SHARES (OTCMKTS:MRPHF)’s short sellers to cover MRPHF’s short positions. The stock decreased 2.86% or $0.01 during the last trading session, reaching $0.34. About 203,564 shares traded or 36.26% up from the average. Marapharm Ventures Inc. (OTCMKTS:MRPHF) has 0.00% since June 8, 2017 and is . It has underperformed by 12.57% the S&P500.

Venbio Select Advisor Llc increased Immunomedics Inc (IMMU) stake by 1835.94% reported in 2018Q1 SEC filing. Venbio Select Advisor Llc acquired 16.06 million shares as Immunomedics Inc (IMMU)’s stock rose 31.75%. The Venbio Select Advisor Llc holds 16.94M shares with $247.49 million value, up from 875,000 last quarter. Immunomedics Inc now has $4.07B valuation. The stock decreased 4.40% or $1.12 during the last trading session, reaching $24.32. About 2.08M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 204.95% since June 8, 2017 and is uptrending. It has outperformed by 192.38% the S&P500. Some Historical IMMU News: ; 09/05/2018 – IMMUNOMEDICS 3Q LOSS/SHR 21C, EST. LOSS/SHR 15C; 09/04/2018 – IMMUNOMEDICS APPOINTS DR. ROBERT IANNONE HEAD OF RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER; 09/05/2018 – Immunomedics 3Q Loss $35.5M; 21/05/2018 – Immunomedics Submits Biologics License Application for Sacituzumab Govitecan to the U.S. FDA; 16/05/2018 – lmmunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer; 10/04/2018 – ICYMI: Top AstraZeneca I/O vet Robert Iannone jumps to Immunomedics as R&D chief as BLA looms $IMMU $AZN; 21/05/2018 – IMMUNOMEDICS SUBMITS BLA FOR SACITUZUMAB GOVITECAN TO U.S. FDA; 21/05/2018 – IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION; 12/04/2018 – Immunomedics Closes Above 50-Day Moving Average: Technicals; 21/05/2018 – IMMUNOMEDICS SUBMITS BLA FOR SACITUZUMAB GOVITECAN TO FDA

More notable recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Globenewswire.com which released: “Immunomedics to Present at Jefferies 2018 Global Healthcare Conference” on May 30, 2018, also Prnewswire.com with their article: “Analysts Predict Big Year in Biotech M&A” published on June 08, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on June 07, 2018. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) were released by: Fool.com and their article: “Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today” published on June 04, 2018 as well as Nasdaq.com‘s news article titled: “Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic …” with publication date: June 03, 2018.

Investors sentiment increased to 1.26 in 2018 Q1. Its up 0.19, from 1.07 in 2017Q4. It increased, as 15 investors sold IMMU shares while 46 reduced holdings. 26 funds opened positions while 51 raised stakes. 117.56 million shares or 0.32% more from 117.18 million shares in 2017Q4 were reported. Lord Abbett And Communication Lc accumulated 935,328 shares. Parallax Volatility Advisers Lp reported 11,092 shares. Swiss Bancorp holds 211,650 shares or 0% of its portfolio. Susquehanna Gru Limited Liability Partnership holds 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 760,481 shares. 2.11 million are held by Jennison Assocs. Arrowmark Colorado Ltd Liability holds 4.95 million shares. Northern Trust Corporation, Illinois-based fund reported 1.26M shares. Great West Life Assurance Co Can has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Cubist Systematic Strategies Lc, Connecticut-based fund reported 20,657 shares. Metropolitan Life Insurance Communications New York invested in 31,092 shares or 0% of the stock. 185,415 are owned by Guggenheim Capital Ltd Liability Corporation. Td Asset Management holds 170,800 shares. Investors holds 0% or 785,000 shares in its portfolio. Rhumbline Advisers has invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Gp One Trading LP has invested 0.05% in Immunomedics, Inc. (NASDAQ:IMMU).

Since February 28, 2018, it had 0 insider buys, and 1 insider sale for $2.05 million activity. 117,729 shares were sold by GOLDENBERG DAVID M, worth $2.05M.

Among 4 analysts covering Immunomedics (NASDAQ:IMMU), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immunomedics had 18 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Thursday, August 17. The stock has “Buy” rating by Jefferies on Thursday, October 6. The rating was maintained by Cowen & Co on Wednesday, December 6 with “Buy”. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 16. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Buy” rating by Jefferies on Friday, June 9. The firm has “Hold” rating by Jefferies given on Tuesday, March 15. The rating was maintained by Wells Fargo on Monday, June 4 with “Buy”. The firm earned “Buy” rating on Thursday, May 17 by Wells Fargo. The firm has “Market Perform” rating by Wells Fargo given on Tuesday, June 21. The stock has “Buy” rating by Jefferies on Monday, October 9.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>